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Abstract 
Background:  Irritable bowel syndrome (IBS) is a gastrointestinal disorder manifested by 
abdominal discomfort or pain, bloating and abdominal distension, and changes in the 
defecation pattern between diarrhoea and constipation. A significant proportion of IBS 
patients attribute their symptoms to food items and food intolerance. More information is 
needed on the effect of diet management in the treatment of IBS and this thesis is a 
contribution with effort to advance our knowledge about this aspect of the disorder.  
 
Aim: To investigate the diet and quality of life in IBS patients in comparison with the 
background population. Furthermore, to study the effects of guidance on diet management on 
changes in food intake, quality of life and symptoms.  
 
Design and methods: The study group included 35 healthy controls, 36 unguided IBS 
patients and 43 IBS patients who received guidance in diet management two years earlier. 
The controls and patients were asked to complete a Food Frequency Questionnaire (FFQ), a 
Short -Form Nepean Dyspepsia Index (SF-NDI) questionnaire, an Irritable Bowel Syndrome- 
Quality Of Life questionnaire (IBS-QOL) and a Birmingham IBS symptom score 
questionnaire. 
 
Results: With or without dietary guidance, there were no statistical differences in the intake 
of calories, carbohydrates, proteins and fat between the IBS patients and the controls. IBS 
patients made a conscious choice to avoid some foods belonging to the FODMAP group 
(fermentable oligosaccharides, disaccharides, monosaccharides and polyols). However, they 
consumed other food items which are rich in FODMAPs and avoided food sources which are 
important for their health. Two years after receiving guidance on diet management, IBS 
patient had a different diet profile. They consumed less FODMAP-rich foods, consumed more 
foods with probiotic supplements and less frequently avoided food sources that were 
important for their health as compared with unguided IBS patients. In addition, quality of life 
was improved and IBS symptoms was reduced. 
 
Conclusion: Although at the first sight the diet of IBS patients does not seem to differ from 
that of the background population, detailed examination shows avoidance of certain food 
items. Guidance on the management of diet improves their choice of a healthier diet, 
improves quality of life and reduces symptoms.
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1. INTRODUCTION 
 
1.1. IBS 
 
1.1.1 Definition 
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder in the absence of any 
structural, physiological or biochemical abnormalities in the gastrointestinal tract (1). The 
condition is classified as a functional disorder where the diagnosis is based on the symptom 
presented; abdominal discomfort or pain, bloating and abdominal distension, and changes in 
the defecation pattern between diarrhoea and constipation. The degree of symptoms varies in 
different patients from tolerable to severe, where the experience of pain can vary from a 
nagging, colicky, sharp or dull feeling of pain (1). Also the time pattern and discomfort can 
vary immensely from patient to patient. Some complain of daily symptoms, while others will 
report intermittent pain at intervals of weeks/ months. Over the years many different 
definitions have been used to define IBS (e.g. Manning criteria, Rome I, II and III criteria).  
The Manning criteria were originally defined to differentiate between organic disease and IBS 
in patients attending a gastroenterology outpatients clinic on the basis of symptom description 
(1). The five symptoms are listed in box 1. A weakness with this definition is the proportion 
of false-positive IBS diagnoses that occur; which results in under-diagnosing and under-
treatment of other diseases that are overlooked when such false-positives occur. The 
definition also fails to differentiate between the subgroups of IBS (1).  
 
 
 
 
 
 
 
 
The Rome criteria were defined in order to enable more accurate diagnoses of IBS, especially 
in research use, and the definition of subgroups (1). Box 2 lists the second version of these 
Box 1: Manning criteria (1):   
1. Visible abdominal distension 
2. Relief of pain with bowel movement 
3. More frequent bowel movements with the onset of pain 
4. Loose stools at onset of pain 
5. Passage of mucus per rectum 
6. Feeling of incomplete evacuation 
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criteria, a set of guidelines that outlines symptoms and applies parameters such as frequency 
and duration of symptoms (2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Currently the third version of the Rome criteria, based on previous definitions and the 
Manning criteria, is being used. These criteria (listed in box 3) are the basis of a positive 
diagnosis of IBS and have to be present in the absence of any alarm symptoms which include 
fever, anemia, bleeding from the gut, significant weight loss, family history of cancer, 
inflammatory bowel or celiac disease, recent consistent change in bowel habit, persistent and 
daily diarrhea or constipation > 45 years of age or physical findings (e.g. abdominal mass, 
malnutrition). The Rome III criteria are thought to be the most precise criteria for the 
symptom-based diagnosis because of their utilization to identify and enroll patients into 
clinical IBS trials. They are therefore seen as the best criteria to identifying IBS patients (3).  
Additionally, it is important to undertake an evaluation in order to exclude possible organic 
causal factors. Clinical examinations, blood samples, gastroscopy, coloscopy, x-ray of the 
small intestine and abdominal ultrasound are used to eliminate other causes and an IBS 
diagnosis is only given after excluding structural or biochemical abnormalities.  
 
Box 2: The Rome II criteria: 
At least 12 weeks, which not need to be consecutive, in the preceding 12 months 
of abdominal discomfort or pain that has two out of three of the following 
features (2): 
1. Relief by defecation 
2. Onset associated with a change in frequency of stool 
3. Onset associated with the change in form (appearance) of stool 
 
Symptoms that cumulatively support the diagnosis are: 
 abnormal stool frequency (greater than 3 bowel movements per day or less than 
3 bowel movements per week; 
 abnormal stool form (lumpy/hard or loose/watery stool); 
 abnormal stool passage (straining, urgency or feeling of incomplete 
evacuation); 
 passage of mucus; 
 bloating or feeling of abdominal distention. 
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The supportive symptoms mentioned above can also be used to sub classify IBS patients into 
three subtypes: Diarrhea -predominant, constipation-predominant and alternating 
constipation/ diarrhea-predominant. Diarrhea-predominant IBS (IBS-D) is less frequent than 
the constipation form and  is also more difficult to manage, as it can have a severe effect on 
ones social life. Diarrhea is defined as an altered stool consistency (looser) and an elevated 
stool frequency compared with healthy subjects. Constipation-predominant IBS (IBS-C) is 
involving infrequent defecation (less than three times per week), hard or lumpy stools, and/or 
straining during a bowel movement (4). Alternating bowel habits also occur and these patients 
experience both diarrhea and constipation alternately (IBS-M).  
 
1.1.2 The prevalence of IBS 
The estimated prevalence of IBS varies from 12% to 30 %, a large variation that may be 
explained by the use of different definitions in different studies (3). A cross-sectional 
population-based survey conducted in Oppland and Hedmark Counties in Norway using 
Box 3: The Rome III criteria: 
Recurrent abdominal pain or discomfort, associated with two or more of the 
following, at least 3 days/month in the last 3 months (2): 
1. Improvement with defecation 
2. Onset associated with a change in frequency of stool 
3. Onset associated with the change in form (appearance) of stool 
 
The criteria must be fulfilled for the last 3 months with symptom onset at least 6 
months prior to diagnosis. 
Symptoms that cumulatively support the diagnosis are: 
 abnormal stool frequency (greater than 3 bowel movements per day or less than 
3 bowel movements per week; 
 abnormal stool form (lumpy/hard or loose/watery stool); 
 abnormal stool passage (straining, urgency or feeling of incomplete 
evacuation); 
 passage of mucus; 
 bloating or feeling of abdominal distention. 
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recent diagnostic criteria estimated the prevalence among the Norwegian population to be 
8,1%  (5).  There is a female predominance, with as much as twice as many women than men 
being diagnosed in most parts of the world. This higher prevalence in females is found 
regardless of the criteria used for diagnosis (3). IBS symptoms are prevalent in all age groups 
and the onset is not excluded to early adulthood. But younger patients are more likely to be 
affected than elderly and the prevalence of IBS diminishes in patients older than 60 years of 
age (6). This observation remains unexplained, but it is likely that several interacting factors 
play an effective role.  
Research estimates that as many as 25-45 % of persons who experience symptoms similar to 
IBS-symptoms avoid seeking medical treatment (7, 8), suggesting that the estimated 
prevalence should be higher than studies report.  
   
1.1.3 Impact on quality of life 
IBS symptoms  may vary from tolerable to severe, and can severely affect the daily activities 
of many patients. Patients with IBS have been found to have a considerably reduction in 
quality of life as manifested by poorer sleep and problems with employment, relationships, 
sexual functioning, leisure, travel and diet (9, 10).  IBS reduces quality of life to the same 
degree of impairment as major chronic diseases such as congestive heart failure, hepatic 
cirrhosis, renal insufficiency and diabetes (9, 11, 12).  
 
1.1.4 Socioeconomic aspects of IBS  
Although few persons with IBS actually seek medical care (7, 8), IBS is still the most 
common gut disorder in primary healthcare, gastrointestinal clinics and in the general 
population (13, 14). As a result, patients with IBS constitute one of the largest diagnostic 
groups in the gastroenterological setting. The diagnosis remains an elimination diagnosis and 
given its prevalence and epidemiology, it is not surprising that IBS has the potential to impose 
a substantial financial burden on the society (15). The disorder  has been shown to be 
associated with significant direct (use of health resources) and indirect (loss of workdays and 
loss of productivity during work) costs, where the latter accounts for most of the financial 
burden associated with IBS (16).  Lacking a definite biological marker results in prescription 
of numerous medical examinations where one of the main goals is to exclude any organic 
disorders. Annual direct costs including number of medical consultations and diagnostic tests 
(excluding prescription and over-the-counter drug costs) in the treatment of IBS is estimated 
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to be between $1.7 billion and $10 billion in the United States (15). IBS is also implicating in 
significant indirect costs to society in that it mainly strikes people of working age, a group 
that represent the economic output power of society. On average, IBS patients miss 13.4 days 
of work and school per year (4, 8). A study conducted on IBS patients in the United Kingdom 
and United States concluded that this patient group has a higher probability of losing a job, 
quitting work or turning down a promotion, and that patients work fewer hours as a result of 
their condition (17). The annual indirect costs in the United States are estimated at up to $20 
billion (18). 
 
 
1.2  Nutrition 
 
1.2.1  General nutrition in IBS 
Although little is known about the pathological link between diet and IBS, it is well known 
that the patients' diet is greatly affected. Patients associate their IBS symptoms with the 
ingestion of food, combinations of foods, or a meal itself. Postprandial worsening of 
symptoms and adverse food reaction is common; bloating, flatulence and abdominal pain are 
especially of major importance (19). A study conducted on IBS patients in Sweden showed 
that 64% of the patients experienced a postprandial worsening of symptoms; 28% of these 
within 15 minutes after eating and 93% within 3 hours (20). Accordingly, most patients with 
IBS believe diet plays a significant role in their symptoms and 51-63% have reported that they 
are interested in knowing what foods to avoid (20, 21). Many IBS patients report problems 
with specific food items, most commonly implicating milk and milk products, wheat products, 
caffeine, certain meat, cabbage, onion, peas/beans, hot spices and fried food as the offending 
foods (20, 22). The proposed mechanisms behind this food related problems includes 
abnormal gas handling in the gastrointestinal tract, abnormal colonic fermentation, 
exaggerated motor responses after meals, psychological factors, and intolerance to specific 
foods (23). Such postprandial symptoms experienced by IBS patients may results in a 
changed and sometimes limited diet, though the data are conflicting. A Norwegian study on 
food intolerance and IBS showed that 62% of the subjects had limited or excluded food items 
from their daily intake and 12% of these had made such drastic changes to their diet that 
health damage could be possible in the long run (24). Other dietary surveys among IBS 
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patients in the community have however failed to detect such differences in dietary 
composition between IBS patients and community controls (25, 26). Nevertheless, diet seems 
to play an important role in the pathophysiology and management of IBS patients, though the 
exact mechanism is not clearly outlined (see the following sections).  
 
1.2.2 Meal size 
Large portion sizes have been shown to affect symptom response in IBS patients. Several 
studies on IBS have shown an exaggerated increase in rectal sensitivity to distension after a 
meal (27).  
 
1.2.3 Food allergy and intolerance 
IBS patients identify trigger foods that they feel induce symptoms (such as dairy, fructose, 
wheat products, and caffeine) and describe worsening of their symptoms shortly after food 
ingestion. In a survey including more than 1200 individuals with IBS the participants were 
asked what lifestyle changes they had made or considered for treatment of IBS. Their answers 
included small meals (69%), avoiding fatty foods (64%), increased fiber intake (58%), and the 
avoidance of milk products (54%), carbohydrates (43%), caffein (41%), alcohol (27%) and 
high-protein foods such as meat (21%) (28). Studies have proposed a number of dietary 
factors to produce IBS-like symptoms, such as sugar malabsorption (29), fiber intake (30) and 
lipids (27), but unfortunately there are no consistent findings. Organic causes to these reported 
adverse reactions to food may be food poisoning, food allergy, or food intolerance. The latter 
two will be discussed further.  
 
An allergic response is based on the development of immunoglobulin E (IgE)-type antibodies 
against a food constituent, for example as seen in fish and peanut allergies. There is little 
evidence that the global food-related symptoms in IBS are caused by food allergy (31), but 
studies suggest that immune-mediated reactions to food (food allergy or hypersensitivity) are 
probably responsible for IBS symptoms in a small proportion of this group of patients (21, 
32).  
 
Food intolerance is a non-immune-mediated adverse reaction to food and may be caused by 
factors within food, such as pharmacologic agents (histamine, sulfites and caffeine), enzyme 
deficiency (lactase deficiency), metabolic disorders (galactosemia, alcohol intolerance), or 
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idiosyncratic responses (32). Studies have shown, that there are important potentiating 
interactions between food intake, motility and visceral sensation among IBS patients. These 
interactions may directly lead to symptoms. One study describes a nutrient-dependent 
exaggeration of both the sensory component of the gastrocolonic response (27) and of rectal 
sensitivity to balloon distension (33).  
 
1.2.4 FODMAP 
Poorly absorbed, highly fermentable short-chain carbohydrates and sugar alcohols have the 
potential, through their osmotic effects and rapid fermentability by bacteria in the distal small 
bowel and colon, to potentiate IBS symptoms and cause metabolic reactions like bloating and 
diarrhea (34). These are collectively called FODMAPs (fermentable oligosaccharides, 
disaccharides, monosacharides and polyols), are widespread in the diet, and comprise 
monosaccharides (e.g. excess fructose), disaccharides (e.g. lactose), oligosaccharides (e.g. 
fructans and galactans) and polyols. A complete list of food items rich in FODMAPs and 
alternative foods, can be found in Appendix A. FODMAPs are hypothesized to be a trigger 
behind gastrointestinal symptoms in people with visceral hypersensitivity or abnormal 
motility responses. They operate largely by inducing luminal distention through a 
combination of osmotic effects and gas production due to rapid fermentation by bacteria in 
the small and proximal large intestine (35, 36). Such malabsorption can occur for a number of 
reasons, including the deficiency of luminal enzymes hydrolyzing the glycosidic bonds in 
carboydrates (oligosaccharides; fructans and galactans), the absence or low activity of brush 
border enzymes (e.g. lactase) or presence of low-capacity epithelial transporters (fructose, 
GLUT2, GLUT5) (37). Restricting the intake of these carbohydrates globally (as opposed to 
individually) has in recent studies shown symptom reduction in functional disorders such as 
IBS (36, 38). It is noteworthy that these malabsorptions are individual and the FODMAP list 
in Appendix A is a complete listing of all foods that may cause symptoms, not a list of food 
items one has to exclude as an IBS patient. It is therefore recommended that food items be 
tested one by one, preferably together with a dietitian, to prevent unnecessary avoidance of 
foods items.  
 
Lactose  
Patients who get symptoms from lactose -containing foods (mostly milk and milk products) 
are probably hypersensitive to unabsorbed carbohydrate and have a reduced lactase 
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production in the small bowel brush border. This is a common condition worldwide and both 
individuals with and without IBS may report increased symptoms. Additionally, lactose 
intolerance has not been found to play a role in IBS patients (39). Nevertheless, limiting 
lactose intake may help reduce the symptoms in some patients (40).  
 
Fructose, fructans and galactans 
Fructose is a monosaccharide found in three main forms in the diet: As free fructose (fruits, 
fruit juices, table sugar and honey), in the disaccharide sucrose, or as fructans (FOS; fructose 
oligosaccharides). While free fructose is slowly absorbed along the border of the small 
intestine, fructans are hardly absorbed at all (41).  
Fructans are naturally occurring, nonstructural storage carbohydrates in various plants, and 
are found in wheat, onion, spring onions, shallots, leeks, artichokes and chicory (41). An 
additional source of fructans is inulin (mostly as a long-chain fructan) which is increasingly 
being added to foods for its presumed prebiotic effect (38). Unabsorbed, fructose and fructans 
may act as osmotic agents, drawing fluid into the intestinal lumen and creating distention of 
the small intestine. This can lead to the sensation of bloating, abdominal distention, 
discomfort and pain (21). This symptom production seems to be related to the fermentative 
effect of colonic bacteria on the malabsorbed carbohydrates (42) and may trigger symptoms 
especially in those who have underlying viceral hypersensitivity, like IBS patients (43). Some 
authors also suggest that an increased fermentative capacity in IBS patients may be the cause 
of such a reaction (44). Studies have shown that a fructose or fructan load can provoke acute 
gastrointestinal symptoms in IBS, and one-third of patients with suspected IBS have been 
reported to be fructose intolerant (43). In another study, as many as 72 % of patients fitting 
the Rome II criteria of functional abdominal bloating and gas-related symptoms, displayed 
sugar malabsorption (44). Coingestion of glucose enhances fructose absorption significantly 
and thus reduces symptom production. This is because glucose stimulates fructose absorption 
in a dose-dependent fashion, and malabsorption will only occur when fructose is present in 
excess of glucose (41). With fruits such as berry fruits (strawberry, raspberry), stone fruits 
(peach, plum, apricots), bananas and pineapples, glucose is present in equal or greater 
amounts as fructose and no symptoms are produced when ingested. In contrast, foods such as 
honey, oranges and dates consist of more fructose than glucose, and fruits such as cherries, 
apples, pears, grapes, mango and watermelon have excess of both fructose and sorbitol. These 
fruits may therefore cause symptoms in those with gastrointestinal hypersensitivity (33).  
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Galactans (stacchyose and raffinose) are chains of galactose molecules with one fructose 
molecule on the end. These carbohydrates act in the same manner as fructans in the 
gastrointestinal tract and may produce the same symptoms when consumed by IBS patients 
(38). Galactans-rich foods are legumes (soy, beans, chickpeas, lentils), cabbage and brussel 
sprouts.  
 
Polyols 
The most common sugar alcohols (also referred to as polyols) are sorbitol, mannitol, maltitol, 
lactitol and xylitol, where sorbitol constitutes the one most used and consumed. Small 
amounts of sorbitol are present in apples, pears, cherries, apricots and plums, and it is a 
common additive in sugar-free foods such as chewing gum, candy, mints, jelly, jam, drinks 
and chocolate (44).  
The mixture fructose-sorbitol is absorbed more poorly and evokes more severe symptoms 
than either sugar or fructose alone, both in normal patients and in patients with IBS (41), a 
fact that seems to be important in the understanding of IBS. The prevalence of fructose plus 
sorbitol malabsorption in IBS is similar to that in healthy controls, where ingestion of 10g 
sorbitol (the amount present in two medium pears) caused moderate to severe abdominal 
discomfort in 17% of healthy subjects (45). However, IBS patients experienced significantly 
more symptoms than healthy subjects after combined fructose sorbitol ingestion, whereas no 
differences were seen after the consumption of fructose or sorbitol alone (46). 
 
Unblinded, uncontrolled observational studie shows that 40-75% of IBS patients experience 
significant improvements in symptoms after following diets restricted in malapsorbed sugars 
such as lactose, fructose and/or sorbitol (43, 47, 48). Because of the study design one cannot 
exclude placebo effect in these trials, but a long-time sustained response to sugar-restricted 
diets in other studies argues against this as a possible placebo effect would diminish over time 
(49). A fructose- and sorbitol restricted diet both reduced gastrointestinal symptoms and 
significantly improved mood and early signs of depression in fructose malabsorbers (50). 
Also, a general FODMAP approach to dietary interventions has recently been used by 
restricting fructans in addition to fructose, thus a global restriction. The results provide strong 
evidence that fructose and fructans are dietary triggers for IBS-like symptoms when fructose 
malabsorption is present, and suggest that this effect is caused by the restriction of poorly 
absorbed short-chain carbohydrates and not due to a placebo effect (35, 36, 38).  
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1.2.5 Fiber 
Dietary fiber is non-starch polysaccharides derived from plant foods that are poorly digested 
by human enzymes (51). It occurs naturally in grains, fruits and vegetables, as well as in 
seeds, nuts and legumes, and can be divided into groups of water-soluble and -insoluble fiber. 
The reported low intake of dietary fiber among IBS patients suggests that adding dietary fiber 
in the diet can have a beneficial effect. Today the dietary fiber intake in Norway is 16-19 
g/day (52) compared to the recommended >25 g/day (53). Increased consumption of dietary 
fiber has been thought to accelerate oro-anal transit and decrease intracolonic pressure, and 
therefore play a role in the management of IBS-symptoms, particularly in constipation (IBS-
C, possible IBS-M) (54). Unfortunately, recent studies show inconsistent results (30, 55, 56) 
on this effect. One of the problems with the trials conducted is that their focus has to a large 
extent been on fiber as a whole, and few studies have made the distinction between insoluble 
and soluble fiber. Looking at the two forms separately, soluble fiber is seen to have a greater 
symptom improvement effect than insoluble fiber (21). While insoluble fiber has been shown 
to increase symptoms in some studies (30), a recent randomized, double-blinded, placebo-
controlled trial of soluble fiber showed a significant reduction of intensity of abdominal pain, 
constipation, diarrhea, as well as improvement in performance of daily activities on minor 
functional bowel disorders (57).  
 
1.2.6 Probiotics 
Probiotics are defined as live microorganisms which, when administered in adequate amounts, 
have a therapeutic potential for gastrointestinal disease (58). Probiotics can occur naturally in 
fermented foods such as yoghurt, sour cream and fermented fish. It can also be added to other 
foods, tablets or liquids as pure or mixed cultures of organisms. Meta-analysis and reviews 
have been conducted on probiotics and IBS, concluding that probiotics may be beneficial as 
treatment. Suggested mechanisms behind such effects may be an increased mucosal anti-
inflammatory and reduced proinflammatory cytokines, direct modulation of intestinal pain, 
blockage of the actions of potentially pathogenic bacteria on toll-like receptors, and enhancing 
the mucosal barrier function (59). Unfortunately there are many variables affecting the results, 
such as type and amounts probiotics used, short duration time, the size and the characteristics 
of the IBS groups studied (21). All in all, there is growing evidence that probiotics may be an 
important factor in the treatment of IBS, but additional studies are needed.  
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1.2.7 Gluten and wheat 
Gluten hypersensitivity, in the form of celiac disease, has several symptoms in common with 
the diagnosis criteria of IBS and recent studies suggest that approximately 0.4-4% of patients 
with IBS symptoms have celiac disease (60-62). This either indicates that many patients with 
undiagnosed celiac disease may be wrongly diagnosed as having IBS or that there is an 
unknown association between the two diseases. This nonceliac adverse reaction to wheat 
could also be related to the fructan level in wheat (47). As a major source of fructans in the 
diet, wheat is likely to be problematic when consumed in large amounts in food such as pasta, 
breakfast cereals, bread, cakes, cookies, and crackers. Wheat is comparatively low in fructans 
(1-4g/ 100g) compared to many vegetables and fruits, but its use as a dietary staple means that 
it is the major contributor to fructans in the western world (63). Dietary trends in United 
States and Europe indicate increasing consumption of these food items. But there is no need 
for an absolute elimination of grains in the diet, similar to the gluten-free diet used in the 
treatment of celiac disease, and not all forms of grains needs to be avoided. Some grain have a 
higher tolerability, also in IBS patients. For example, rye contains fructans with longer chain 
lengths than in those found in wheat, and may therefore not have the same osmotic activity or 
be as rapidly fermented. Alternative bread types such as spelt bread, contain less fructans 
(0.06g per portion eaten) than bread made of wheat (64). In one study, spelt bread was seen to 
have lowest levels of fructans and total FODMAPs (64). This may be the reason why many 
IBS patients benefit from changing from wheat to spelt bread (65). 
Other data indicate that a large proportion of patients with IBS symptoms are gluten sensitive, 
without meeting the criteria for the diagnosis of celiac disease (66). There is some acceptance 
of the idea that a persistent low-grade inflammation may be present in some IBS patients. 
Several causal factors have been proposed, such as small-bowel bacterial overgrowth, 
postinfectious causes and immune-mediated responses to specific dietary constituents such as 
gluten (32). 
 
1.3 The aim of the study 
 
The present study was undertaken to investigate the diet and quality of life in IBS patients in 
comparison with that of the background population. Furthermore, it aimed at studying the 
effects of guidance on diet management, as regards changes in food intake, quality of life and 
symptoms. 
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2. METHODS 
 
2.1 Patients and healthy subjects 
 
Patients were recruited from among those who were referred to the gastroenterology section, 
Stord Helse-Fonna Hospital (unguided) and those who received diet guidance two years 
earlier at Stord Hospital (guided). Patients between 18 and 65 years of age who satisfied 
Rome III criteria for the diagnosis of IBS were considered for inclusion in the study. Those 
with organic gastrointestinal disease, clinically significant system disease, and pregnant or 
lactating women were excluded. Patients who had undergone any abdominal surgery, with the 
exception of appendectomy, caesarean and hysterectomy, were also excluded. Healthy 
volunteers without any gastrointestinal complaints and without any of the exclusion criteria 
were recruited as controls by local announcement to students at the University of Bergen and 
hospital employees. The study was performed in accordance with the Declaration of Helsinki 
and was approved by the local Committee for Medical Research Ethics. All patients gave 
written consent.  
 
2.2 Study design 
 
Four questionnaires were sent by mail to both patient groups (guided and unguided) and 
controls during October 2010 with a following reminder sent mid December 2010. These 
questionnaires were Food Frequency Questionnaire (FFQ), Short-Form-Nepean Dyspepsia 
Index (SF-NDI) quality of life questionnaire, Irritable Bowel Syndrome-Quality Of Life form 
(IBS-QOL) and Birmingham IBS Symptom score. The participants were asked to answer the 
questionnaires and return them by mail.  
 
2.3  Guidance on diet management 
 
Guidance on diet management was given two years prior to the study. The patients were 
asked to keep a diary where they included time of eating/drinking and type of food and drinks 
ingested daily. Furthermore, they reported the occurrence of pain, abdominal distention, stool 
frequency and consistency. This was done for at least a month. Symptoms were graded as 
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light, moderate or severe. Two sessions, of about an hour each, were scheduled with a nurse, 
where information about the disease and the role of diet were emphasized and a review of the 
diary was done together with the patient. The information was given verbally using charts and 
illustrative drawings. Diet instructions focused on avoiding foods that previous patients had 
reported causing symptoms (65), the importance of regular meals and healthy eating habits 
(Table 1). This diet guidance given at Stord Hospital two years ago correlates well with the 
FODMAP foods investigated in studies in recent years (Appendix A). Additionally, fiber-poor 
diets and trials with fat, protein, carbohydrates rich/poor diet were tried. With the 
participation of the patient, the nurse designed a suitable diet for the patient (65). The 
intention behind this change of diet was to reduce the production of pain- and discomfort-
causing intestinal gas, to stimulate useful bacteria and to reduce/increase the release of 
gastrointestinal hormones.  
 
Table 1: General food advice given to IBS patients at Stord Hospital.  
Food allowed  Food advised to avoid  
Spelt and spelt products 
Meat 
Fish 
Chicken 
Fat and oils 
Rice 
Potatoes 
Carrot 
Apple and pear (peeled) 
Citrus 
Tomato 
Milk 
Coffee, tea 
Chocolate 
Alcohol 
Probiotic foods  
Flour 
Pasta 
Onion 
Garlic 
Paprika 
Cabbage and rutabaga 
Carbonated beverages (soda) 
Light products (food containing artificial 
sweeteners) 
Banana 
Beans 
Peas  
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2.4  Questionnaires used 
 
The questionnaires used in this study were Food Frequency Questionnaire (FFQ), Short Form 
Nepean Dyspepsia Index (SF-NDI), Irritable Bowel Syndrome Quality Of Life (IBS-QOL) 
and Birmingham IBS Symptom score. All the questionnaires was sent to the subjects by mail 
and the results are based on self-reporting.  
 
2.4.1 MoBa Food Frequency Questionnaire (Moba FFQ) 
A semi-quantitative Food Frequency Questionnaire (FFQ) is a common dietary assessment 
tool used in large epidemiologic studies of diet and health. The self-administrated FFQ asks 
participants to report the frequency of consumption and portion size of line items over a 
defined period of time. Each line item is defined by a series of foods or beverages. Additional 
questions on food purchasing and preparation methods enable the analysis software to further 
refine nutrient calculations. Although FFQs are not considered appropriate for estimating true 
nutrient intake at the individual level, they can be used in epidemiological studies to rank 
individuals along the distribution of intake, so that individuals with low intakes can be 
separated from those with high intakes (67). The FFQ used in this study is developed by the 
Norwegian Institute of Public Health for the Norwegian Mother and Child Cohort Study 
(MoBa). A validation of this questionnaire was conducted on healthy pregnant women in 
2008 in Oslo, Norway (68). The MoBa FFQ is a semi-quantitative questionnaire that asks 
about the intake of 225 food items, including any oral supplements, grouped according to the 
Norwegian meal pattern and is designed to capture the participant's dietary habits during the 
previous 12 months (Appendix B). Data analysis gives information about intake of energy, 
water, macro and micro nutrients, minerals and alcohol in addition to 100 specific food 
groups and items (A complete listing of these groups and items are found in Appendix C). It 
also gives information about meal patterns.  
 
2.4.2 Short-Form Nepean Dyspepsia Index (SF-NDI) 
The Short-Form (SF) Nepean Dyspepsia Index (NDI) was primarily constructed and validated 
in patients with functional dyspepsia (69). A Norwegian translation of the form was later 
validated and proved to also perform well in patients, most of whom satisfied the Rome II 
criteria for IBS, with subjective food hypersensitivity (70). The form is a 10-item 
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questionnaire (Appendix D) examining the influence of dyspepsia on domains of health in 
patients, namely tension/anxiety, interference with daily activities, disruption to regular 
eating/drinking, knowledge towards/control over disease symptoms and interference with 
work/study, with each subscale containing two items. Each item is measured by a 5-point 
Likert scale ranging from 1 (not at all or not applicable), 2 (a little), 3 (moderately), 4 (quite a 
lot) to 5 (extremely). Individual items in each sub-scale are aggregated to obtain a score range 
from 10 (lowest Health Related Quality of Life, HRQoL, score) to 50 (highest HRQoL score) 
as per the developers' original calculation formula. High scores indicates worse functioning or 
symptoms.  
 
2.4.3 Irritable Bowel Syndrome Quality Of Life (IBS-QOL)  
The IBS-QOL is a 34-items-long IBS-specific, quality of life document concerning physical 
and psychosocial functioning as a result of IBS (71). A 5-point Likert response scale is used 
to assess how much the statement described the feeling of the respondent: not at all, slightly, 
moderately, quite a lot, and extremely (Appendix E). IBS-QOL consists of 8 domains: 
dysphoria, interference with activity, body image, health worry, food avoidance, social 
reaction, sexual function, and impact on relations. The IBS-QOL has been validated in IBS 
patients (72). Low scores indicates a reduction in quality of life related to these domains.  
 
2.4.4 Birmingham IBS symptom questionnaire 
The Birmingham IBS symptom score questionnaire is a disease specific score to measure the 
symptoms of patients with IBS. It has been developed to be suitable for self-completion and 
has been found to be acceptable to patients. Its dimensions have good reliability, external 
validity and sensitivity (73). The questionnaire is comprised of 11 questions based on the 
frequency of IBS related symptoms (Appendix F). Each question has a standard response 
scale with symptoms all being measured on a 6-point Likert scale ranging from 0 ("none of 
the time") to 5 ("all of the time"). There are three underlying dimensions: pain (3 items), 
diarrhea (5 items) and constipation (3 items) (73). 
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2.5 Statistical analysis 
 
Comparisons between three groups, controls, unguided IBS and guided IBS patients were 
performed with the Kruskal-Wallis non-parametric ANOVA test and Dunn's test as a post-
test. To compare between two groups, unguided IBS and guided IBS patients, the Mann-
Whitney non-parametric test was used. All tests were two-tailed and probabilities (P) less than 
0,05 were considered statistically significant. All analysis were done using GraphPad Prism 5 
(GraphPad Software, Inc., LaJolla, California, USA).  
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3.  RESULTS 
3.1 Patients and healthy subjects 
 
Forty-two controls, 63 unguided IBS patients and 70 guided IBS patients were enrolled in the 
study. Seventy-nine IBS patients replied and signed a written consent. Eight letters were 
returned by mail because the patients moved to a new address, which we were unable to trace. 
Ten patients returned the questionnaires unanswered and did not give their consent to 
participate in the study. These patients were six unguided and four guided patients. Thirty-six 
patients did not reply or return the questionnaire. Thus, 35 controls, 36 unguided IIBS patients 
and  43 guided IBS patients satisfactorily completed the study. The mean age in controls, 
unguided IBS patients and guided IBS patients were 31 (range 20-54), 38 (range 19-61) and 
40 (range 20-63) years, respectively. There was no statistical difference between the mean age 
in the three groups. The percentage of males in the unguided IBS patient group, guided IBS 
patient group and controls were 19%, 12% and 14%, respectively. 
 
3.2 Effect on diet and diet management 
3.2.1 MoBa Food Frequency Questionnaire 
The FFQ showed that there were no statistical differences in the intake of calories, 
carbohydrates (total, starch and fiber), proteins, fat (total, saturated, cholesterol, trans, 
monounsaturated or polyunsaturated) or sugar between controls, unguided and guided IBS 
patients (Table 2). Nor was there any statistical difference in number of meals or meal pattern 
among the patient groups or between the patients and controls (Figure 1). A significant lower 
consumption of alcohol was reported in both guided and unguided IBS patients as compared 
with controls (Table 2). Accordingly, there was also a significant lower intake in the 
consumption of beer and wine when comparing guided (P=0.0095 and 0.0163, respectively) 
and unguided IBS (P=0.0008 and 0.0017, respectively) patients with controls. The daily 
consumption of beer and wine was 45.0 ± 10.9 and 34.2 ± 5.9 ml in controls, 13.9 ± 5.9 and 
14.5 ± 4.3 ml in unguided patients and 21.0 ± 6.5 and 16 ± 2.9 ml in guided patients (mean + 
SEM). No statistical differences were reported in alcohol consumption or intake of beer/wine 
among the two IBS patient groups.  
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Table 2: Daily intake of macro nutrients and alcohol in controls, unguided IBS patients and guided IBS patients. 
Expressed as mean ± S.E.M 
 Controls Unguided Guided 
Energy, kcal 2338.7 ± 143.6 2102.9 ± 120.0 2243.2 ± 123.8 
Carbohydrates    
- total, g 287.2 ± 19.1 257.2 ± 18.2 278.4 ± 19.6 
- starch, g 139.5 ± 11.8 129.9 ± 10.9 124.9 ± 8.1 
- fiber, g 32.5 ± 2.2 30.0 ± 2.5 31.5 ± 2.1 
Protein 94.4 ± 5.8 81.3 ± 3.8 91.2 ± 4.2 
Fats    
- total, g 86.4 ± 5.5 81.2 ± 4.7 82.9 ± 5.3 
- saturated, g 32.4 ± 2.3 28.9 ± 1.7 30.0 ± 1.7 
- cholesterol, mg 267.8 ± 17.0 261.2 ± 12.3 296.7 ± 16.7 
- trans, g 2.0  ± 0.2 1.8 ± 0.2 1.7 ± 0.1 
- monounsaturated, g 29.9 ± 2.1 27.1 ± 1.7   28.3 ± 2.2 
- polyunsaturated, g 15.7 ± 1.1 17.2 ± 1.4 16.8 ± 1.5 
Sugar, g 51.3 ± 6.3 48.1 ± 5.5 53.9 ± 5.7 
Alcohol 4.7 ± 0.7 1.9 ± 0.4 
A
***
 C
** 2.3 ± 0.4 
A: unguided patients vs controls 
C: guided patients vs controls 
**:  P<0.01 
***: P<0.001 
 
Figure 1: Meal pattern per week among controls, unguided IBS patients and guided IBS patients. Expressed as mean. 
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The difference in the intake of  milk and milk products between IBS patients and controls is 
summarized in Table 3. The calcium intake in unguided IBS patients was significantly lower 
than intake in guided patients and controls (P=0.033 and  P=0.020, respectively). The values 
are listed in table 4.   
 
 
 
Table 3: Daily intake of  dairy products compared between controls, unguided and guided IBS patients. 
Expressed as mean  ± S.E.M. 
 Controls Unguided Guided 
Dairy products    
Milk products, whole fat, g 53.0 ± 30.4 26.2  ± 9.8 20.3 ± 7.7 
Milk products, low-fat, g 267.9 ± 50.9 72.8 ± 18.9
 A
**
 B
** 195.8 ± 55.7 
Sour milk with probiotic 
supplement
1
, g 
100.5 ± 50.4 64.2 ± 19.7
 
 151.6 ± 38.6 
C
** 
Yoghurt, g 108.2 ± 42.3 60.9 ± 15.7 64.2 ± 10.8 
Soy, rice and oat milk, g 1.2 ± 1.0 36.2 ± 25.2 12.6 ± 7.1 
Brown goat cheese, g 4.8 ± 2.1 2.9 ± 1.0 3.6 ± 1.2 
Cheese, whole fat, g 14.7 ± 1.8 17.0 ± 3.0 14.2 ± 2.8 
Cheese low fat, g 4.2 ± 1.8 2.1 ± 1.0 2.4 ± 0.8 
Mold cheese, g 0.94 ± 0.3
 
 0.8  ± 0.7
 A
* 0.3 ± 0.1
 C
** 
1: Includes the brand "Tine Biola" containing LGG® (Lactobacillus rhamnosus GG), and the brand "Tine 
Cultura" containing Lactobacillus acidophilus La-5 and Bifidobacterium Bb-12. 
A: unguided patients vs controls 
B: unguided vs guided patients 
C: guided patients vs controls 
*:  P<0.05 
**:  P<0.01 
 
 
The results of intake of vegetables and fruit are given in table 4, with a more thorough 
description in table 5 of micronutrients and minerals actually consumed.  
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Table 4: Comparison of daily intake of  some vegetables, fruits and berries among controls, unguided and 
guided IBS patients. Expressed as mean  ± S.E.M. 
 Controls Unguided Guided 
Vegetables     
Raw vegetables, g 45.2 ± 7.2  18.9 ± 3.2 
A
*** 39.4 ± 7.3 
Cauliflower, raw, g 1.6 ± 0.3 1.8 ± 0.5 1.9 ± 0.2 
Cauliflower, cooked, g 7.6 ± 1.1   9.6 ± 1.6 10.3 ± 1.6 
Broccoli, raw, g 2.3 ± 0.3  2.6 ± 0.9
 B
** 5.4 ± 1.1 
C
* 
Broccoli, cooked, g 8.2 ± 1.2 6.2 ± 1.1 8.8 ± 1.3 
Peas, g 2.9 ± 0.2 7.3 ± 2.7 4.6 ± 1.2 
Cabbage, raw, g 1.8 ± 0.2 1.5 ± 0.1 4.2 ± 1.8 
Cabbage, cooked, g 2.5 ± 0.2 4.9 ± 2.0 4.7 ± 1.9 
Paprika, raw, g 9.9 ± 1.5
 
 4.7 ± 0.9 
A
** 7.9 ±2.2
 C
* 
Paprika, cooked, g 3.2 ± 0.6 3.5 ± 0.7 3.2 ± 0.6 
Onion, leak, garlic, g 12.6 ± 1.8 7.5 ± 1.2 
A
* 7.9 ± 1.8
 C
** 
Tomatoes, g 78.8 ± 8.6  38.1 ± 4.5 
A
*** 59.0 ± 7.1 
Potatoes, fried, g 4.6 ± 0.7  8.0 ± 1.0 
A
* 6.6 ± 0.9 
Potatoes, cooked, g, 
mashed or gratinated, g 
34.4 ± 3.9  51.1 ± 6.1 
A
* 58.8 ± 5.8
 C
** 
Fruits/ berries, g    
Orange, g 43.8 ± 11.7 50.4 ± 10.9 88.2 ± 17.1 
Banana, g 37.1 ± 4.7 35.0 ± 6.9 51.2 ± 13.0 
Grapes, g 12.0 ± 1.8 22.5 ± 7.5 20.1 ± 5.4 
Pears, g 19.0 ± 3.8 34.4 ± 9.9  16.9 ± 4.2 
Apple, g 66.3 ± 11.0 50.8 ± 13.3 54.9 ± 7.1 
Peach, g 14.7 ± 3.4 23.3 ± 14.3 15.9 ± 4.2 
Grapefruit, g 3.9 ± 1.1 3.0 ± 0.5 10.0 ± 6.1 
Kiwi, g 12.9 ± 6.7 13.7 ± 4.5 14.2 ± 3.2 
Mango, g 4.8 ± 0.8 5.5 ± 1.5 4.8 ± 0.8 
Plums, g 4.8 ± 1.0 6.7 ± 2.2 6.0 ± 1.3 
Melon, g 8.1 ± 1.3 14.2 ± 4.1 8.2 ± 0.9 
Blueberry, g 12.0 ± 2.7 23.6 ± 11.7 14.5 ± 3.1 
Strawberry, g 13.2 ± 3.4 22.8 ± 8.5 14.1 ± 4.9 
Dried fruits    
Prunes, dried, g 1.7 ± 0,4 9.8 ± 7.9 3.5 ± 1.1 
Apricot, dried, g 2.3 ± 0,5 6.8 ± 3.5 6.2 ± 2.7 
Others    
Mushrooms, g 5.8 ± 1.0  3.2 ± 0.9 
A
** 5.9 ± 1.6 
Green beans, g 1.7 ± 0.3  0.7 ± 0.3 
A
* 0.9 ± 0.2 
A: unguided patients vs controls 
B: unguided vs guided patients 
C: guided patients vs controls 
*:  P<0.05 
**:  P<0.01 
***: P<0.001 
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Table 5: Comparison of daily intake of vitamins and minerals based on reported food consumption, among 
controls, unguided and guided IBS patients. Expressed as mean ± S.E.M 
 Controls Unguided Guided 
Vitamins    
Beta-carotene, mg 3.6 ± 0.5 2.5 ± 0.3 
A
*
 B
*
 3.9 ± 0.5 
Folate, µg 278.2 ± 23.3 257.3 ± 17.8 296.4 ± 19.2 
Niacin equivalents, µg 33.8 ± 1.9 30.1 ± 1.3 33.7 ± 1.6 
Retinol equivalents, mg 1.3 ± 0.1 1.0 ± 0.1
A
* 1.2 ± 0.1 
Riboflavin, mg 2.1 ± 0.2 1.6 ± 0.1
A
*
 B
* 1.9 ± 0.1 
Thiamin, mg 1.6 ± 0.1 1.3 ± 0.1 1.5 ± 0.1 
Vitamin B6, mg 1.6 ± 0.1 1.4 ± 0.1
 B
* 1.7 ± 0.1 
Vitamin B12, µg 6.3 ± 0.5 5.6 ± 0.4 6.3 ± 0.5  
Vitamin C, mg 128.0 ± 11.9 134.9 ± 14.7 167.7 ± 18.0 
Vitamin D, µg 3.9 ± 0.3 3.8 ± 0.3 3.8 ± 0.3 
Vitamin E, mg 12.0 ± 1.0 12.3 ± 1.3 12.5 ± 0.9 
Minerals    
Calcium, mg 1184.3 ± 126.6 825.8 ± 65.1
A
*
 B
* 1065.1 ± 82.3
 
Cupper, mg 1.5 ± 0.1 1.3 ± 0.1 1.5 ± 0.1 
Iron, mg 12.0 ± 0.8 10.8 ± 0.6 11.0 ± 0.6 
Magnesium, mg 449.3 ± 29.2 373.2 ± 22.2 
A
* 433.1 ± 26.8 
Phosphorus, mg 1890.2 ± 133.7 1490.0 ± 81.1 
A
* 1768.4 ± 103.6 
Potassium, mg 4259.7 ± 268.6 3632.6 ± 225.3  4355.7 ± 271.3 
Selenium, µg 60.8 ± 3.6 54.6 ± 2.7 61.3 ± 3.1 
Sodium, mg 2988.5 ± 162.7 2799.8 ± 152.1 2866.4 ± 139.4 
Zink, mg 12.3 ± 0.8 10.4 ± 0.5 11.4 ± 0.6 
A: unguided patients vs controls 
B: unguided vs guided patients 
*:  P<0.05 
 
 
 
 
The findings of the differences in wheat and wheat products in controls, unguided and guided 
IBS patients is shown in table 6. The intake of rice, millet and couscous was 38.1 ± 5.6 g/day, 
22.1 ± 3.9 g/day and 34.5 ± 4.9 g/day in controls, unguided and guided patients, respectively, 
which reflects a significant lower consumption among unguided patients as compared with 
both guided IBS patients (P=0.02) and controls (P=0.001). 
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Table 6: Comparison of daily intake of  wheat and wheat products among controls, unguided and guided 
IBS patients. Expressed as mean  ± S.E.M. 
 Controls Unguided Guided 
White bread 63.7 ± 13.5 97.1 ± 20.0 72.3 ± 12.5 
Dark bread 105.1 ± 17.8 71.1 ± 17.6 73.1 ± 12.9 
Spaghetti, pasta 29.1 ± 4.4
 
 18.9 ± 3.7 
A
** 17.8 ± 3.1
 C
** 
Waffles, pancakes 8.4 ± 1.0 8.1 ± 1.2 10.0 ± 1.6 
Cakes 7.5 ± 1.1 6.5 ± 0.8 8.7 ± 1.4 
Crisp bread 16.5 ± 3.5 16.1 ± 3.5 17.6 ± 4.7 
Buns 5.7 ± 1.2
 
 3.3  ± 0.6
 A
* 3.8 ± 1.2
 C
** 
A: unguided patients vs controls 
C: guided patients vs controls 
*:  P<0.05 
**:  P<0.01 
 
 
 
 
3.3 Effect on quality of life 
 
3.3.1 Short-Form Nepean Dyspepsia Index (SF-NDI) 
The reduction in quality of life in unguided patients, guided patients and healthy controls 
amounts to 31.6 ± 1.6, 22.7 ± 1.2 and 10.9 ± 0.3, respectively (mean ± S.E.M) (Figure 2). The 
reduction in quality of life as assessed by the SF-NDI form was significantly lower in the 
guided patients as compared with the unguided patients (P=0.0001). Both patient groups had 
significantly lower quality of life than controls (both P<0.0001).  
 
3.3.2 Irritable Bowel Syndrome Quality Of Life (IBS-QOL) 
One guided patient did not answer this questionnaire. The total score of quality as measured 
by the IBS-QOL questionnaire was significantly improved in the guided patients compared 
with unguided IBS patients (p=0.015). All the domains were significantly improved in guided 
IBS patients except health worry, food avoidance and sexual function (Table 7).  
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Figure 2: The decrease in life quality assessed by SB-NDI, comparing controls, unguided and guided IBS 
patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7: The scores of the 8 domains of the IBS quality of life questionnaire, comparing unguided and 
guided IBS patients. Shown as mean ± S.E.M. 
 Unguided Guided P
 
N 36 42 0.0668 
Total score 68.5 ± 2.0 75.4 ± 2.1 0.0151* 
Dysphoria 65.3 ± 2.7 77.8 ± 2.2 0.0009*** 
Interference with activity 70.2 ± 2.5 78.5 ± 2.1 0.0072** 
Body image 60.3 ± 2.2 70.3 ± 2.5 0.0020** 
Health worry 73.3 ± 2.4 78.5 ± 2.3 0.0929 
Food avoidance 59.4 ± 3.3 59.4 ± 2.6 0.9920 
Social reactions 73.4 ± 2.5 83.8 ± 2.3 0.0035** 
Sexual relations 75.6 ± 3.4 81.0 ± 3.2 0.1156 
Impact on relations 73.3 ± 2.9 81.0 ± 2.1 0.0352* 
*:  P<0.05 
**:  P<0.01 
***: P<0.001 
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3.4 Effect on symptoms 
 
3.4.1 Birmingham IBS Symptom Questionnaire 
The total score of symptoms as assessed by the Birmingham IBS symptom questionnaire was 
lower but not significantly reduced in the guided compared to the unguided IBS patients. Nor 
were there any statistical differences between the occurrence of diarrhea and constipation in 
the two groups. The dimension of pain was significantly reduced in patients who had been 
given dietary advices (Table 8 and figure 3).  
 
Table 8: The scores of the 3 dimensions of the Birmingham IBS Symptom questionnaire in unguided and 
guided IBS patients. Expressed as mean ± S.E.M. 
 Unguided Guided P
 
N 36 43 0.0668
 
Total score 22.4 ± 0.9 19.7 ± 1.2 0.0840
 
Pain 7.9 ± 0.4 6.5 ± 0.5 0.0310*
 
Diarrhea 7.0 ± 0.6 6.1 ± 0.5   0.1436
 
Constipation 7.4 ± 0.6 7.0 ± 0.6 0.6270
 
*:  P<0,05 
 
 
Figure 3: The score of the dimensions in the Birmingham IBS Symptom questionnaire; total score (A), pain 
(B), diarrhea (C) and constipation (D), in unguided and guided IBS patients.  
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4.  DISCUSSION 
 
It is often stated that diet has a major role in triggering symptoms in IBS. Several dietary 
factors have been implicated but dietary trials have produced mixed results and have in 
general given little guidance for the management of IBS. Recent studies have illuminated the 
effect of a FODMAP-restricted diet in this patient group with good results. In the treatment 
program at Stord Hospital the patients have been given similar dietary advice as with a 
FODMAP-restricted diet. In the present study, an attempt was made to evaluate the effect of 
such dietary guidance two years after guidance.  
 
4.1 Discussion of the results 
 
4.1.1 Effect on diet and diet management 
In the present study, there were no statistical differences in the macro nutrients when 
comparing the two patient groups with the control group; which is a sign of low risk of 
malnutrition among IBS patients. However, the unguided and guided patients had a lower 
daily energy intake than controls; 2103 ± 120 kcal, 2243 ± 124 kcal and 2339 ± 144 kcal 
(mean + SEM), respectively. As the same applies for the mean consumption of carbohydrates, 
proteins and fats, this indicates that unguided IBS patients generally eat less food than 
controls and guided patients. This is comparable with other studies on IBS and diet (24). That 
patients given dietary advice in general eat more than unguided patients may be due to 
improved symptoms and/or reassurance through acquired knowledge (74, 75). The significant 
lower alcohol consumption in the patient groups compared to controls in the present study 
correspond well with previous reported intolerance to various alcoholic beverages among IBS 
patients and that as many as 12% either limit or avoid such beverages (20, 24). 
 
Dairy products 
The most important dietary source of calcium in the Western world is milk and other dairy 
products, and the calcium content of these foods can contribute 50-75% of the daily dietary 
intake (76). The common believe among IBS patients that lactose is a main cause of their 
symptoms (77) can be the cause of the lower consumption of milk and milk products that is 
found among unguided IBS patients in this study. This, in turn, can explain the observation 
DISCUSSION 
 
34 
 
made here of a lower intake of calcium in these patients. IBS patients who did not receive 
guidance on diet management consumed only one third of the milk and milk products as 
controls. Also, they had a much higher consumption of alternative milk products such as soy, 
rice and oat milk compared with IBS patients that received guidance on diet management (3 
times as such) and controls (30 times as much). This seems to be a result of a conscious 
choice to replace lactose containing food items in their diet. But despite such replacement 
(instead of exclusion of food items) unguided IBS patients still had a significant lower intake 
of calcium than IBS patients that received guidance on diet management and controls (826 
mg/day versus 1065 mg/day and 1185 mg/day, respectively). This is in accordance with the 
recommendation (800 mg/day) for the age group 20-60 years (78). The recommendation for 
those between 18 and 20 years is 900mg/day (78) and the reported intake in unguided patients 
in this age group may imply an existing risk of not meeting their daily calcium needs. Milk 
and milk products are also abundant in phosphorus and contribute 20-30% of the daily 
phosphorus intake (76). The reduced consumption of these food items is most likely the cause 
of the significant lower intake of phosphorus when comparing unguided IBS patients with 
controls. Unguided IBS patients also had a significant lower intake of the vitamin riboflavin, 
and as milk counts for an average of 25-30% of the riboflavin in Western diet (76), this may 
explain such deviation from the control values.  
 
The guided IBS patients report a consumption rate of sour milk products containing probiotics 
almost twice as much as that of the unguided IBS patients and one and half times that of 
controls. This may be as a result of the dietary advices given them. The products reported 
used were supplemented with Lactobacillus rhamnosus GG, Lactobacillus acidophilus La-5 
and Bifidobacterium Bb-12. Patients with IBS have fewer Lactobacillus spp. and 
Bifidobacterium spp. in their intestinal flora than healthy individuals (79). These bacteria 
have shown to bind to epithelial cells and inhibit pathogen binding and to enhance barrier 
function (80). Furthermore, these bacteria spp. do not produce gas on fermenting 
carbohydrates, an effect which would be amplified as they also inhibit the Clostridia spp 
(bacteria potentially pathogenic to humans) (80). Several studies have shown a reduction in 
flatulence and abdominal distention with an accompanying reduction in composite IBS 
symptom score following probiotic intake (80, 81). The increase in consumption of sour milk 
products containing probiotics by guided IBS patients may increase their tolerance to food 
rich in FODMAPs. 
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Wheat and wheat products 
Unfortunately, the MoBa FFQ does not make it possible to get exact information on the 
patients' consumption of spelt containing food items. Several patients had, however, added 
spelt products on a question asking about additional food items not named in the 
questionnaire. In clinical practice, IBS patients who received guidance on diet management 
were advised to use spelt-bread and spelt products instead of wheat products. The guided 
patients were also advised to avoid pasta (containing wheat), and the consumption of pasta, 
rice, millet, couscous and buns reported by both patient groups were significant lower that of 
controls. Pasta and couscous are products made using durum wheat which tends to be high in 
FODMAP, while rice tends to be low (64). The unguided patients also reported  a significant 
lower consumption of  rice, millet and couscous compared with guided patients and controls.  
 
Fruits and vegetables  
The significant lower consumption of some vegetables (raw vegetables, raw broccoli, paprika, 
onion, leaks, garlic, tomatoes, mushrooms and green beans) is most likely the reason for the 
significant lower intake of retinol equivalent, beta-carotene and magnesium in unguided IBS 
patients compared with controls. Although not significant, a lower consumption of cabbage, 
raw broccoli and cooked potatoes also was reported. 
The total vitamin A content of foods is expressed as µg retinol equivalents, which is the sum 
of provided by retinols and carotenoids. No significant difference was observed on the intake 
of retinol, so difference in intake of beta-carotene is most likely causing the significant 
difference in retinol equivalent intake among the groups. The significant lower intake of 
paprika, broccoli and tomatoes (foods rich in beta-carotene) in IBS patients compared with 
controls might explain such results. 
Magnesium is found abundantly in legumes (beans and peas), nuts and seeds, and whole, 
unrefined grains. The reported lower consumption of beans and dark bread (contains 
unrefined grains) in unguided patients compared to controls may be the cause of this 
significant difference in magnesium intake. Although there were no statistical differences 
found when comparing the consumption of white and dark bread in patient groups and 
controls, there was a marked difference in the amount consumed. Both unguided and guided 
patients reported a lower consumption of dark bread compared to controls, while the unguided 
patients also had a considerably higher intake of white bread in their daily diet.  
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There was a significant lower intake of vitamin B6 in unguided IBS patients compared with 
that in guided patients. Food items such as bananas, beans, milk and vegetables are rich on 
vitamin B6 and the lower consumption of these items among unguided patients might explain 
this difference. 
Fruit tend to be high in potassium and although not significant, the intake of potassium in 
unguided patients was markedly lower than that in the guided patients and controls (P= 
0.0500 and P=0.0670, respectively).  
 
None of the vitamin and mineral intakes in the unguided patients mentioned above were lower 
than the daily recommended intake. Even so, it is worth noticing that the mean reported intake 
for magnesium, calcium and vitamin B6 in unguided IBS patients are at the borderline of 
recommended levels (78). As the reported intake is an estimated mean of the group, there is a 
risk that a proportion of the patients fall short of the estimated requirements.   
 
The unguided IBS patients reported a higher consumption of grapes, pears, peach, peas, 
mango, plums and melon compared to guided patients and controls. These are all fruits and 
vegetables that are rich in FODMAPs, documented as causal symptom factors in IBS (35, 36) 
and advised to avoid in the dietary guidance at Stord Hospital. Such increased consumption of 
FODMAP food among unguided patients compared to guided patients may be a sign of the 
need for information and knowledge about diet in IBS patients. It is noteworthy that the 
advice given at Stord Hospital is that peeled apple and pears are "safe" to eat, as most of the 
fructans are found in the peel. Although not significantly different, the consumption of dried 
prunes and apricots was higher in the IBS patients as compared with controls and also among 
patient groups (unguided higher than guided patients). This could be attributed to the laxative 
effect on patients with constipation dominated IBS. Also, a significant lower intake of green 
beans and mushrooms was seen when comparing unguided patients with controls. These are 
legumes and vegetables rich on polyols and oligosaccharides, and the lower consumption may 
be the result of a conscious choice to avoid foods related to symptom production though 
experience.   
 
 
Not so surprisingly, the treated patients who had been advised about foods to avoid reported a 
lower consumption of these items although they consumed more of the fruits and vegetables 
mentioned above (except pears and mango) than the controls. Better compliance with dietary 
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advices and more information about FODMAPs could help patients in making right dietary 
choices and further improving symptoms.  
 
4.1.2 Effect on quality of life 
The present study showed that both unguided and guided IBS patients have a reduced quality 
of life score compared with healthy controls as assessed by SF-NDI. This reduction in quality 
of life is less in guided IBS patients. While controls said they only had 1.8% decrease in 
quality of life, guided patients reported 45.4% and unguided patients as much as 63.2% 
decrease due to gastrointestinal problems. This is in accordance with previous reports  (9-12).  
 
Furthermore, the quality of life as assessed by IBS-QOL showed that quality of life was 
significantly higher in guided IBS patients than in those who were unguided, which is in 
accordance with previous research using non-pharmacological approaches such as education 
and diet management (35, 65). Of the eight domains analyzed there was significant 
improvement in the areas of dysphoria, interference with activity, body image, social 
reactions and impact on relations, and although improvement there was no statistical 
difference on the domains health worry and sexual relations in patients after guidance. This is 
consistent with other studies on IBS, diet and diet management (65, 82). When comparing the 
two patient groups, there was surprisingly little difference in their reported quality of life 
related to food avoidance. This in spite of the dietary advices given guided patients, and that 
their reported dietary habits may suggest otherwise. 
 
 
4.1.3 Effect on symptoms 
Although all the dimensions evaluated using the Birmingham IBS Symptom Questionnaire 
were improved when comparing unguided patients with guided ones, only pain was 
statistically different. The mean degree of constipation was almost equal when comparing 
unguided patients with guided patients. This may be explained by the fact that IBS patients at 
Stord Hospital two years ago were advised to increase their consumption of fiber in general, 
dietary advice that was found beneficial in some trials (51) as mentioned earlier. As more 
research was conducted on this subject, conflicting results arose and the increased 
consumption of dietary fiber as a whole worsened symptoms in IBS patients in some trials 
(30, 55, 56). The focus has therefore now shifted  towards dietary fiber types, insoluble and 
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soluble, and the different effect these have on IBS symptoms. As a consequence, the diet 
advice given today at Stord Hospital is to increase the consumption of soluble fibers through 
the diet and to reduce the intake of insoluble fibers.  
 
4.2 Limitations of the study 
 
4.2.1 Study design and protocol 
Ideally, to see if there has been a direct change in diet management after a treatment program 
such as the one used at Stord Hospital, one should have followed the same patient group from 
admission into the program and two years on. This would give more information of the 
correlation between the patients dietary habits, symptoms and quality of life. Because of the 
time limit posed by a master thesis, this was not possible.  
 
It is noteworthy that the ratio of females to males in this study was 7:1, which is higher than 
the IBS gender ratio in the general population (3). One should be cautious, therefore, when 
applying the results and conclusions drawn here on male IBS patients.  
 
The control group was not randomly selected, which potentially could cause bias in the 
results. As students or hospital employees, the healthy controls may be better informed about 
health and a healthy lifestyle than the general population; a knowledge that may affect their 
own lifestyle and diet. They may also be more physical active compared to IBS patients, as 
IBS symptoms often affect the ability to be physically active (as shown in this study and 
others) (9-12). Studies indicate that increased physical activity affects energy intake in a 
positive direction (83) and may improve gastrointestinal problems such as constipation (84).  
 
The questionnaires used contained no direct questions on the patient's subjective experience 
of possible improvement of symptoms or effects of diet management. Nor did they contain 
questions about which diet advice gave best results or if the patients still followed the advice 
two years after guidance. The results in this thesis therefore only gives an assumption 
regarding diet, diet management and the improvement on symptoms and quality of life.  
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4.2.2 Food Frequency Questionnaire 
Although FFQs are not considered appropriate for estimating true nutrient intake at the 
individual level, they can be used in epidemiological studies to rank individuals along the 
distribution of intake, so that individuals with low intakes can be separated from those with 
high intakes (67). Compared with short-term records, the FFQ also provides a better 
approximation of the habitual diet over a longer period (85). However, there are a few 
problems associated with the FFQ. The patient may not always remember his/her accurate 
intake and there is a tendency of underreporting (women more than men) of energy intake 
determined from such self-reporting dietary assessment methods as the FFQ (86, 87). To get a 
more exact nutrient intake at the individual level in IBS patients, one could use a self-
administrating 24 hours dietary recall form in a four to seven days period instead of the FFQ. 
This may give more detailed dietary information and could be given several times (e.g. 3 
times) during a year to get the habitual diet over time. To examine the relationship between 
diet and symptoms, such diet form can be combined with a symptom score (similar to the 
diary used at Stord Hospital, but made easier to self-report). However, this method will affect 
inclusion of patients as it require more time and effort from participants, as well as the 
duration time of the study.  
 
While this study was being conducted, a new FFQ designed to estimate the consumption of  
FODMAPs in the diet, in addition to macro- and micronutrients, was developed, validated and 
published (88). This or a similar FFQ may be more accurate when investigating the effect of 
dietary guidance on FODMAPs as done here.  
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5 CONCLUSION 
 
In their diet, IBS patients make a conscious choice to avoid food items assumingly causing 
symptom production. However, they also consume other food items rich in FODMAPs that 
might increase symptom production.. Further, they avoid food sources which are important 
for their health. Two years after guidance, IBS patients who received two hours' guidance on 
diet management had a different diet profile than unguided patients. They consumed less  
FODMAP-rich foods, consumed more probiotic containing foods and less frequently avoided 
food sources that were important for their health as compared with unguided IBS patients. In 
addition, quality of life was improved and IBS symptoms was reduced. 
 
6. FUTURE ASPECTS 
 
 
It would be interesting to follow the same group of IBS patients over time and investigate 
possible changes in diet, symptoms and quality of life when comparing the groups before and 
after diet guidance. One could also use alternative food registration methods to stronger relate 
dietary habits with symptom production and quality of life. It would then be easier to analyze 
for  correlation between the results, and also evaluate for any dietary differences among the 
IBS subgroups. Another aspect interesting to examine, is the patients' compliance with dietary 
advice and their subjective experience of any results associated with such advice.  
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Appendix A  FODMAP list (38) 
 
 
FODMAP Excess 
fructose 
Lactose Oligosaccharides 
(fructans and/or 
galactans) 
Polyols 
High 
FODMAP 
food 
sources 
Fruits: 
Apples, pears, 
peaches, mango, 
sugar snap peas, 
watermelon, 
tinned fruit in 
natural juice 
Milk: 
Cow, goat and 
sheep (regular 
and low-fat), ice 
cream, condensed 
and evaporated 
milk, milk 
powder 
Fruits: 
Watermelon, custard 
apple, white 
peaches, rambutan, 
persimmon  
 
Fruits: 
Apples, 
apricots, 
cherries, 
longon, 
lychee, nashi 
pears, 
nectarine, 
pears, peaches, 
plums, prunes, 
watermelon 
     
 Honey Yoghurt: 
(regular and low-
fat) 
Vegetables: 
Artichokes, 
asparagus, beetroot, 
Brussels sprout, 
broccoli, cabbage, 
fennel, garlic (large 
amounts), leeks, 
okra, onions (also 
onion powder), 
spring onion, peas, 
shallots. 
Vegetables: 
Avocado, 
cauliflower, 
mushrooms, 
snow peas 
     
 Sweeteners: 
Fructose, high 
fructose corn 
syrup, corn syrup 
solids 
Cheeses: 
Soft and fresh 
(e.g. ricotta, 
cottage) 
Legumes: 
Chickpeas, lentils, 
red kidney beans, 
baked beans 
Sweeteners: 
Sorbitol (420), 
mannitol 
(421), xylitol 
(967), maltitol 
(965), isomalt 
(953) and 
other endings 
in "-ol" 
 Large total 
fructose dose: 
Concentrated 
fruit sources; 
large serves of 
fruit, dried fruit, 
fruit juice.  
Others: 
Dairy desserts, 
custard, 
margarine 
Cereals: 
Wheat and rye when 
eaten in large 
amounts (e.g. bread, 
pasta, couscous, 
crackers, biscuits) 
 
   Sweeteners: 
Inulin 
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FODMAP Excess 
fructose 
Lactose Oligosaccharides 
(fructans and/or 
galactans) 
Polyols 
Suitable 
alternative low-
FODMAP 
 food sources 
Fruit: 
Banana, 
blueberry, 
carambola, 
durian, 
grapefruit, 
grape, 
honeydew 
melon, 
kiwifruit, 
lemon, lime, 
mandarin, 
orange, 
passionfruit, 
raspberry, 
strawberry 
Milk: 
Lactose-free, 
rice milk, gelati 
(ice cream), 
sorbet  
 
 
 
 
 
 
Butter 
 
 
 
 
Vegetables: 
Bamboo shoots, bok 
choy, carrot, celery, 
capsicum, corn, 
eggplant, green 
beans, lettuce, 
chives, parsnip, 
pumpkin, silverbeet.  
Fruit: 
Banana, 
blueberry, 
carambola, 
durian, 
grapefruit, 
grape, 
honeydew 
melon, 
kiwifruit, 
lemon, lime, 
mandarin, 
orange, 
passionfruit, 
raspberry, 
strawberry 
     
 Honey 
substitute: 
Maple syrup, 
golden syrup 
Cheese: 
"Hard" 
cheeses, 
including brie 
camembert 
Substitute for 
onion/garlic: 
Garlic-infused oil 
 
     
 Sweeteners: 
Any except 
polyols 
Yoghurt: 
Lactose-free 
Cereals: 
Gluten-free and spelt 
bread/ cereal 
products 
Sweeteners: 
Sugar 
(sucrose), 
glucose, other 
artificial 
sweeteners not 
ending on "ol" 
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Appendix B MoBa Food Frequency Questionnaire 
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Appendix C MoBa Food Frequency Questionnaire 
   Complete list of data analysed 
 
 
Macro nutrients 
 
Water Cholesterol 
Energy (kcal) Total carbohydrates 
Total protein Starch 
Total fat Fibres 
Saturated fat Mono- and disaccharides 
Total trans fat Sugar 
Monounsaturated fat Alcohol 
Polyunsaturated fat  
 
 
Vitamins and minerals 
 
Retinol Calcium 
Beta-carotene Iron 
Retinol equivalent Sodium 
Vitamin D Potassium 
Vitamin E Magnesium 
Thiamine Zink 
Riboflavin Selenium 
Niacin Cupper 
Niacin equivalent Phosphor 
Vitamin B6  
Folate  
Vitamin B12  
Ascorbic acid  
 
 
Food items 
 
White bread Fish toppings, oily fish Jam 
Brown bread Seafood Honey 
Butter Shellfish Chocolate spread 
Margarine Tuna Vegetable pâté 
Light margarine Liver, eggs (fish) Sugar/honey on porridge or  
Brown goat cheese, "Prim" Meats (fatty) in tea/coffee 
Cheese, fatty Meats (lean)  
Cheese, lighter Turkey, turkey orders  
Mold cheese Mayo, mayo salads  
 
 
Eggs Soy, rice and oat milk Alcohol-free beer 
Seagull eggs Orange and apple juice Beer 
Cereals, porridge Vegetable juice Wine 
Cornflakes Artificially sweetened drinks Liquor/spirits 
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Dairy products, whole-fat Sugary soft drinks/soda Coffee 
Dairy products, low-fat  Sugary "saft" Decaffeinated coffee 
Sour milk Water, spring/bottle Black tea 
Yoghurt  Green tea/ herbal tea 
 
 
 
  
Turkey or chicken sausage Entrails Pizza, taco 
Mixed products of meat Poultry Soup 
Beef Wildfowl Potatoes, cooked, mashed, gratinated   
Pork Fish, lean Potatoes, fried 
Bacon Fish, oily Spaghetti, pasta 
Stew meat Fish, mixed products Rice, millet, couscous 
Lamb Vegetables as main course Sauces 
Wild Mustard Tomato sause 
  Olive oil 
 
 
Vegetables, boiled Onion, leek, garlic Orange 
Vegetables, raw Paprika, raw Banana 
Cauliflower, raw Paprika, cooked Grapes 
Cauliflower, cooked Tomatoes Apple 
Broccoli, raw Potatoes, fried Peach 
Broccoli, cooked Potatoes, cooked, mashed,  Grapefruit 
Peas gratinated Kiwi 
Cabbage, raw Mushroom Mango 
Cabbage, cooked Green beans Plums 
Almonds, nuts  Melom 
  Blueberry 
  Strawberry 
 
 
 
Desserts, dairy Crackers Prunes, dried 
Waffles, pancakes Artificially sweeteners  Apricots, dried 
Bun, rolls Rice pudding  
Cakes Flour, grain, grain products  
Chocolate Sweet cookies  
Candy   
Marzipan   
Snacks   
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Appendix D Short Form - Nepean Dyspepsia Index 
    
      SF-NDI 
    (Spørreskjema om livskvalitet) 
(sett kryss ved ett tall) 
 
    Spenning 
1. Har ditt følelsesmessige velvære vært forstyrret av dine mageplager i løpet av de siste to ukene? 
 
1 p - ikke i det hele tatt 
2 p - litt 
3 p - en del 
4 p - ganske mye 
5 p - svært mye 
 
2. Har du vært irritabel, anspent eller frustrert på grunn av dine mageplager i løpet av de siste to 
ukene? 
 
1 p - ikke i det hele tatt 
2 p - litt 
3 p - en del 
4 p - ganske mye 
5 p - svært mye 
 
     Innflytelse på daglige aktiviteter 
3. Har din evne til å holde på med fritidsaktiviteter (rekreasjon, hobbyer, idrett, sosialt samvær 
osv.) vært forstyrret av dine mageplager i løpet av de siste to ukene? 
 
1 p - ikke i det hele tatt 
2 p - litt 
3 p - en del 
4 p - ganske mye 
5 p - svært mye 
 
4. Har gleden ved dine fritidsaktiviteter (rekreasjon, hobbyer, idrett, sosialt samvær osv.) vært 
forstyrret av dine mageplager i løpet av de siste to ukene? 
 
1 p - ikke i det hele tatt 
2 p - litt 
3 p - en del 
4 p - ganske mye 
5 p - svært mye 
 
 
    Spising/drikking 
5. Har mageplagene dine forstyrret deg i hva du har kunnet spise og drikke (inkludert når, hva og 
hvor mye) i løpet av de to siste ukene? 
 
1 p - ikke i det hele tatt 
2 p - litt 
3 p - en del 
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4 p - ganske mye 
5 p - svært mye 
 
6. Har din mulighet til å nyte mat og drikke vært forstyrret på grunn av dine mageplager i løpet av 
de to siste ukene? (Vennligst ta i betraktning din matlyst og hvordan du føler deg etter at du har 
spist eller drukket.) 
 
1 p - ikke i det hele tatt 
2 p - litt 
3 p - en del 
4 p - ganske mye 
5 p - svært mye 
 
    Kunnskap/kontroll 
7. Har du, i løpet av de to siste ukene, lurt på om du alltid kommer til å ha disse mageplagene? 
 
1 p - ikke i det hele tatt 
2 p - litt 
3 p - en del 
4 p - ganske mye 
5 p - svært mye 
 
8. Har du, i løpet av de to siste ukene, lurt på om mageproblemene dine kan skyldes en svært 
alvorlig sykdom (for eksempel kreft eller hjerteproblemer)? 
 
1 p - ikke i det hele tatt 
2 p - litt 
3 p - en del 
4 p - ganske mye 
5 p - svært mye 
 
    Arbeid/studier 
9. Har din evne til å arbeide eller studere vært forstyrret av dine mageplager i løpet av de siste to 
ukene? 
 
1 p - ikke i det hele tatt 
2 p - litt 
3 p - en del 
4 p - ganske mye 
5 p - svært mye 
 
10. Har mageproblemene dine forstyrret trivselen i ditt arbeide eller i dine studier i løpet av de to 
siste ukene? 
 
1 p - ikke i det hele tatt 
2 p - litt 
3 p - en del 
4 p - ganske mye 
5 p - svært mye 
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Appendix E Irritable Bowel Syndrom Quality of Life 
 
IBS-QOL- helse undersøking 
 
Ver venleg og svar på alle spørsmål . Nokre spørsmål verkar like, men dei er ulike. 
 
Navn           persnr.   Dato 
 
1. Eg kjenner meg hjelpelaus på grunn av mageplagene mine: 
 Aldri 
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
 
2. Eg føler at lukta som kjem av tarmproblema mine plagar meg: 
 Aldri 
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
 
3. Eg synest eg brukar for mykje tid på toalettet:  
 Aldri 
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
 
 
4. Eg føler eg har lett for å bli sjuk på grunn av magetarmproblema mine:  
 Aldri 
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
 
5. Eg kjenner meg oppblåst på grunn av tarmproblema mine: 
 Aldri 
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
 
6. Eg føler eg ikkje har kontroll over livet mitt på grunn av tarmproblema:  
 Aldri 
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
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7. Eg føler livskvaliteten er nedsatt på grunn av tarmproblema mine:  
 Aldri 
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
 
8. Eg føler det ubehageleg å snakke om tarmproblema mine: 
 Aldri 
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
 
9. Eg føler meg deprimert på grunn av tarmproblema mine:  
 Aldri 
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
 
10. Eg føler meg isolert frå andre på grunn av tarmproblema mine: 
      Aldri 
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
 
11. Eg må ta hensyn til mykje av maten eg et på grunn av tarmproblema mine: 
  Aldri  
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
 
12. Seksuell aktivitet er vanskeleg for meg på grunn av tarmproblema mine:  
 Aldri 
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
 
 
13. Eg er sint fordi eg har tarmproblem: 
 Aldri 
 Av og til 
 Ofte 
 Svært ofte 
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 Alltid 
 
14. Eg føler at eg irriterer andre på grunn av tarmproblema mine: 
 Aldri 
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
  
15. Eg er redd for at tarmproblema mine skal bli verre: 
  Aldri 
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
 
16. Eg er irritert på grunn av tarmproblema mine:  
 Aldri 
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
 
17. Eg er redd for at andre synest eg overdriv tarmproblema mine: 
 Aldri 
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
 
18. Eg føler at eg gjer lite på grunn av tarmproblema mine: 
  Aldri 
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
 
19. Eg må unngå stress-situasjonar på grunn av tarmproblema mine:  
 Aldri 
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
 
20. Tarmproblema mine reduserer min seksuelle lyst: 
 Aldri 
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
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21. Mine klesval blir begrensa på grunn av tarmproblema mine: 
 Aldri 
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
 
22.Eg må unngå tunge aktivitetar på grunn av tarmproblema mine:  
 
 Aldri 
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
 
23.Eg må vera nøyen med kva eg et på grunn av tarmproblema mine:  
 Aldri 
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
 
24.På grunn av tarmproblema mine, er det vanskeleg for meg å vera med andre som eg 
ikkje kjenner godt:  
 Aldri 
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
 
25.Eg kjenner meg trøytt på grunn av tarmproblema mine: 
 Aldri 
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
 
26.Eg føler meg urein på grunn av tarmproblema mine: 
 Aldri 
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
 
27. Eg kan ikkje ta lange turar eller lange reiser på grunn av tarmproblema mine:  
 Aldri 
 Av og til 
 Ofte 
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 Svært ofte 
 Alltid 
 
 
28. Eg er frustrert over at eg ikkje kan eta kva eg vil på grunn av tarmproblema mine:  
 Aldri 
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
 
29. Det er viktig å vera i nærleiken av toalett på grunn av tarmproblema mine:  
 Aldri  
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
 
30  Livet mitt er sentrert om tarmproblema mine: 
 Aldri 
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
 
31. Eg er redd for å  miste kontroll over tarmen min: 
 Aldri 
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
  
32. Eg er redd for at eg ikkje vil kunna tømma tarmen min: 
 Aldri  
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
 
33.  Tarmproblema mine påverker mine næraste forhold: 
  Aldri 
 Av og til 
 Ofte 
 Svært ofte 
 Alltid 
 
34. Eg føler at ingen forstår seg på tarmproblema mine: 
 Aldri 
 Av og til 
 Ofte 
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 Svært ofte 
 Alltid 
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Appendix F Birmingham Irritable Bowel Syndrome symptom  
   form 
 
 
  Hele 
tida 
Det meste 
av tida 
Ein heil 
del av 
tida 
Av og til Ein liten 
del av 
tida 
Ikkje i det 
heile tatt 
1. Kor ofte har du ubehag eller 
smerte i magen? 
 
      
2. Kor ofte har du problem med 
laus, eller vatn tynn avføring? 
 
      
3. Kor ofte har du problem med 
diaré? 
 
 
     
4. Kor ofte har du hard avføring?  
 
     
5. Kor ofte har du behov for å 
presse, for å få ut avføring? 
 
      
6. Kor ofte har du problem med 
forstoppelse? 
 
 
     
7. Kor ofte har du ubehag eller 
smerte etter at du har spist?  
 
      
8. Kor ofte har du vanskar med å 
sove eller har du våknet på 
grunn av magesmerte? 
      
9. Kor ofte har du problem med å 
halde på avføring? 
 
 
     
10. Kor ofte må du springe til 
toalettet fordi det er vanskelig å 
halde seg?  
 
      
11. Kor ofte har duslim i 
avføringen? 
 
 
     
 
 
